Agenus Inc stock is traded at $6.40, with a volume of 879,998. It is up +3.06% in the last 24 hours and up +5.96% over the past month. Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Previous Close:
$6.21
Open:
$6.17
24h Volume:
879,998
Relative Volume:
1.18
Market Cap:
$289.58M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
3.83
EPS:
$1.67
Net Cash Flow:
-$87.53M
1W Performance:
-11.36%
1M Performance:
+5.96%
6M Performance:
+102.53%
1Y Performance:
+51.30%
1-Day Range:
$5.98$6.50
1-Week Range:
$5.96$7.09
52-Week Range:
$2.71$10.31
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus IncSector
HealthcareIndustry
BiotechnologyPhone
781-674-4410Address
3 FORBES ROAD, LEXINGTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS